SCHEMBL2463852

SCHEMBL2463852

COc1cc(C(F)(F)F)ccc1B(O)O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ENPP2 Q13822 1/20 0.47
MGLL Q99685 2/20 0.44
TRPV1 Q8NER1 1/20 0.42
CYP2C19 P33261 3/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
RAB9A P51151 2/20 0.41
KDM4E B2RXH2 2/20 0.41
USP2 O75604 1/20 0.41
ALDH1A1 P00352 1/20 0.41
HPGD P15428 1/20 0.41
HSD17B10 Q99714 1/20 0.41
HTR2A P28223 1/20 0.41
ORAI1 Q96D31 1/20 0.39
ORAI2 Q96SN7 1/20 0.39
ORAI3 Q9BRQ5 1/20 0.39
TRPV6 Q9H1D0 1/20 0.39
LIPE Q05469 1/20 0.39
CFTR P13569 1/20 0.39
MAPT P10636 3/20 0.39
CYP1A2 P05177 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29954889 1.00 ENPP2 (0.47) ENPP2MGLLTRPV1CYP2C19L3MBTL1
SCHEMBL319585 0.85 ENPP2 (0.47) ENPP2MGLLCYP2C19L3MBTL1RAB9A
SCHEMBL29588618 0.85 ENPP2 (0.47) ENPP2MGLLCYP2C19L3MBTL1RAB9A
SCHEMBL25368443 0.84 MGLL (0.42) MGLLCYP2C19L3MBTL1RAB9AKDM4E
SCHEMBL29957898 0.83 TRPV1 (0.52) ENPP2TRPV1ALDH1A1HPGDHSD17B10
SCHEMBL12118475 0.83 TRPV1 (0.52) ENPP2TRPV1ALDH1A1HPGDHSD17B10
SCHEMBL29954769 0.82 MGLL (0.41) MGLLCYP2C19KDM4EUSP2ALDH1A1
SCHEMBL1042131 0.82 KDM4E (0.39) MGLLCYP2C19L3MBTL1RAB9AKDM4E
SCHEMBL30994957 0.82 KDM4E (0.39) MGLLCYP2C19L3MBTL1RAB9AKDM4E
SCHEMBL29953373 0.81 CYP2C19 (0.51) MGLLCYP2C19L3MBTL1KDM4EUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4735433-A2 SUBSTITUTED PYRIDAZINE COMPOUNDS AS INHIBITORS OF NLRP3 ACTIVITY AND THERAPEUTIC USES THEREOF Viva Star Biosciences (US) Inc. (US) 2026-05-06 EP disclosed
US-20250388585-A1 PRMT5 INHIBITORS AND USES THEREOF GILEAD SCIENCES INC (US) 2025-12-25 US disclosed
US-20250353828-A1 SUBSTITUTED BIARYL ENDOCHIN-LIKE QUINOLONES WITH ENHANCED ANTIPARASITIC ACTIVITY OREGON HEALTH & SCIENCE UNIVERSITY (US) 2025-11-20 US disclosed
US-12448388-B2 PRMT5 inhibitors and uses thereof GILEAD SCIENCES, INC. (US) 2025-10-21 US disclosed
EP-4615830-A1 TRIAZINONE DERIVATIVES AS NLRP3 INHIBITORS F. Hoffmann-La Roche AG (CH) 2025-09-17 EP disclosed
EP-4609865-A2 NLRP3 INHIBITORS F. Hoffmann-La Roche AG (CH) 2025-09-03 EP disclosed
EP-4562009-A1 NOVEL COMPOUNDS AC Immune SA (CH) 2025-06-04 EP disclosed
US-20250163068-A1 COMPOUNDS AND THEIR METHODS OF USE PRAXIS PRECISION MEDICINES, INC. 2025-05-22 US disclosed
EP-4554945-A1 PYRROLOTRIAZINE AND IMIDAZOTRIAZINE DERIVATIVES AS MODULATORS OF THE NLRP3 INFLAMMASOME PATHWAY AC Immune SA (CH) 2025-05-21 EP disclosed
US-20250154107-A1 3,4-Dihydroisoquinolin-1(2H)-Ones Derivatives as STING Antagonists and the Use Thereof BEIGENE SWITZERLAND GMBH (CH) 2025-05-15 US disclosed
US-20100311693-A1 Preparation and Uses of 1,2,4-Triazolo [1,5a] Pyridine Derivatives CEPHALON, INC. (US) 2010-12-09 US disclosed
WO-2010141796-A2 PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a] PYRIDINE DERIVATIVES CEPHALON, INC. (US) 2010-12-09 WO disclosed
US-20090298871-A1 SULFONYL-PHENYL-2H-[1,2,4]OXADIAZOL-5-ONE DERIVATIVES , PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (FR) 2009-12-03 US disclosed
EP-2102198-A1 SULFONYL-PHENYL-2H-[1,2,4]OXODIAZOL-5-ONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS Sanofi-Aventis (FR) 2009-09-23 EP disclosed
US-20080312271-A1 AZABENZIMIDAZOLYL COMPOUNDS PFIZER INC. 2008-12-18 US disclosed
US-20080280933-A1 BENZIMIDAZOLYL COMPOUNDS EFREMOV IVAN 2008-11-13 US disclosed
WO-2008071311-A1 SULFONYL-PHENYL-2H-[1,2,4]OXODIAZOL-5-ONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (FR) 2008-06-19 WO disclosed
WO-2008012623-A1 BENZIMIDAZOLYL COMPOUNDS AS POTENTIATORS OF MGLUR2 SUBTYPE OF GLUTAMATE RECEPTOR PFIZER PRODUCTS INC. (US) 2008-01-31 WO disclosed
WO-2008012622-A2 AZABENZIMIDAZOLYL COMPOUNDS AS POTENTIATORS OF MGLUR2 SUBTYPE OF GLUTAMATE RECEPTOR PFIZER PRODUCTS INC. (US) 2008-01-31 WO disclosed
WO-2000075135-A1 BIARYL INHIBITORS OF PRENYL-PROTEIN TRANSFERASE MERCK & CO., INC. (US) 2000-12-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250388585-A1 PRMT5 INHIBITORS AND USES THEREOF PRMT1, PRMT5, PRMT6 ENPP2 2672/4885MGLL 4217/4885TRPV1 4848/4885
US-20080280933-A1 BENZIMIDAZOLYL COMPOUNDS PAICS, TMBIM6, ABCG2 ENPP2 3972/4885MGLL 1294/4885TRPV1 624/4885
US-20250353828-A1 SUBSTITUTED BIARYL ENDOCHIN-LIKE QUINOLONES WITH ENHANCED ANTIPARASITIC ACTIVITY EPX, TFEB, EPHX1 ENPP2 27/4885MGLL 513/4885TRPV1 4829/4885
US-12448388-B2 PRMT5 inhibitors and uses thereof PRMT5, PRMT1, PRMT9 ENPP2 1547/4885MGLL 4209/4885TRPV1 4878/4885
US-20250163068-A1 COMPOUNDS AND THEIR METHODS OF USE SCN1A, SCN3A, SCN1B ENPP2 384/4885MGLL 2058/4885TRPV1 123/4885
US-20090298871-A1 SULFONYL-PHENYL-2H-[1,2,4]OXADIAZOL-5-ONE DERIVATIVES , PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS PPARD, PPARG, PPARA ENPP2 2500/4885MGLL 1003/4885TRPV1 1244/4885
US-20080312271-A1 AZABENZIMIDAZOLYL COMPOUNDS AZI2, PAICS, UGT2B7 ENPP2 2545/4885MGLL 2573/4885TRPV1 2312/4885
US-20100311693-A1 Preparation and Uses of 1,2,4-Triazolo [1,5a] Pyridine Derivatives CCNA1, CCNY, RB1 ENPP2 2432/4885MGLL 4837/4885TRPV1 4751/4885
US-20250154107-A1 3,4-Dihydroisoquinolin-1(2H)-Ones Derivatives as STING Antagonists and the Use Thereof STING1, IRF3, MAVS ENPP2 22/4885MGLL 1408/4885TRPV1 1047/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.